Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagida Bibi

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|July 23, 2024
Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccinationEve Richardson, Sagida Bibi, Florence McLean, et al.
Human Vaccines & Immunotherapeutics|July 13, 2023
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adultsSue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, et al.
Plos Pathogens|June 26, 2024
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruseAmy Flaxman, Sarah Sebastian, Sofia Appelberg, et al.
Vaccine|August 26, 2025
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)Grace Li, Natalie G Marchevsky, Grace Macaulay, et al.
The Lancet. Infectious Diseases|March 28, 2025
The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trialAnja Saso, Ebrima Kanteh, David Jeffries, et al.
The Journal of Infection|January 18, 2025
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort studyShuo Feng, Sagida Bibi, Parvinder K Aley, et al.
Ebiomedicine|March 1, 2021
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United KingdomPauline Versteegen, Marta Valente Pinto, Alex M Barkoff, et al.
Nature Medicine|September 30, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infectionShuo Feng, Daniel J Phillips, Thomas White, et al.
Ebiomedicine|June 4, 2021
Corrigendum to 'Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom'Pauline Versteegen, Marta Valente Pinto, Alex M Barkoff, et al.
Nature Communications|March 8, 2024
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussisJoshua Gillard, Madeleine Suffiotti, Peter Brazda, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|July 23, 2024
Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccinationEve Richardson, Sagida Bibi, Florence McLean, et al.
Human Vaccines & Immunotherapeutics|July 13, 2023
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adultsSue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, et al.
Plos Pathogens|June 26, 2024
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruseAmy Flaxman, Sarah Sebastian, Sofia Appelberg, et al.
Vaccine|August 26, 2025
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)Grace Li, Natalie G Marchevsky, Grace Macaulay, et al.
The Lancet. Infectious Diseases|March 28, 2025
The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trialAnja Saso, Ebrima Kanteh, David Jeffries, et al.
The Journal of Infection|January 18, 2025
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort studyShuo Feng, Sagida Bibi, Parvinder K Aley, et al.
Ebiomedicine|March 1, 2021
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United KingdomPauline Versteegen, Marta Valente Pinto, Alex M Barkoff, et al.
Nature Medicine|September 30, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infectionShuo Feng, Daniel J Phillips, Thomas White, et al.
Ebiomedicine|June 4, 2021
Corrigendum to 'Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom'Pauline Versteegen, Marta Valente Pinto, Alex M Barkoff, et al.
Nature Communications|March 8, 2024
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussisJoshua Gillard, Madeleine Suffiotti, Peter Brazda, et al.
Pageof 6